Hepatic Arterial Infusion Chemotherapy versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma.

BACKGROUND

Prior to the approval of sorafenib, hepatic arterial infusion chemotherapy (HAIC) was offered to patients with advanced hepatocellular carcinoma (HCC) in East Asia, particularly Japan. According to the Japanese guidelines, HAIC is recommended as one of the treatment options in patients without extrahepatic metastasis (EHM).

METHODS

The present cohort study compared the use of HAIC and sorafenib on outcomes of patients with advanced HCC. Consecutive patients with advanced HCC who received HAIC or sorafenib as a first-line systemic therapy were enrolled from 10 Japanese institutions. The primary outcomes were overall survival (OS) in patients with macrovascular invasion (MVI), but without EHM, and OS in patients without both MVI and EHM.

RESULTS

Between 2009 and 2016, 2,006 patients were enrolled (541 HAIC patients, 1,465 sorafenib patients). After propensity score matching, the OS of patients with MVI but without EHM was significantly longer in the HAIC group compared with the sorafenib group (10.1 vs. 9.1 months for the HAIC and sorafenib groups, respectively;

CONCLUSION

HAIC is a potential front-line treatment choice in a subpopulation of patients with advanced HCC with MVI but without EHM.

Informations de copyright

Copyright © 2020 by S. Karger AG, Basel.

Déclaration de conflit d'intérêts

K.U. received honoraria from Bayer and Eisai, and consulting or advisory fees from Eisai and Eli Lilly. S. Ogasawara received honoraria from Bayer, Eisai, Eli Lilly, consulting or advisory fees from Bayer, Eisai, Merck & Co. Inc., Chugai Pharma, Eli Lilly, and research grants from Bayer and Eisai. M.I. received consulting or advisory fees from Bayer Yakuhin, Eisai, Novartis Pharma, Shire, and MSD, and research grants from Bayer Yakuhin, Kyowa Hakko Kirin, Yakult, Eli Lilly Japan, Ono Pharmaceutical, Eisai, AstraZeneca, Baxalta Japan Limited, Chugai Pharmaceutical, Bristol-Myers Squibb, Merck Serono, Nano Carrier, ASLAN Pharmaceuticals, Novartis Pharma, and Takara Bio. Y.Y. received honoraria from Bayer and an Overseas Research Fellowship from the Uehara Memorial Foundation. T.T. received a consulting or advisory role, speakers bureau, and research funding from Bayer and Eisai. T.Y. received consulting or advisory roles, speakers' bureau, and research funding from Bayer and Eisai. S. Obi received research funding from Eisai, Otsuka pharmaceutical, and Mochida pharmaceutical. T. Ohmura received honoraria from Eisai and Bayer and speakers bureau from Bayer. T. Ohki received speakers bureau from Bayer, Eisai, STARmed, Abbvie, Shionogi, Otsuka Pharmaceutical, and Sumitomo Dainippon Pharma. K.N. received a lecture fee from Pfizer. Y.O. received honoraria from Bayer, Eisai, and Sumitomo Dainippon Pharma. M. Kurosaki received speakers bureau from Eisai and Bayer. K.C. received a consulting or advisory fee from Abbvie, Asuka, Glaxo Smithkline, and speakers bureau from Astellas, Abbvie, Abbot, Eisai, Merck & Co. Inc., Otuka, Olympus Medical Systems, Gilead Sciences, JIMRO, ZERIA Pharmaceutical, Daiichi Sankyo, Taisho Pharmaceutical, Sumitomo Dainippon Pharma, Takeda, Tanabe Pharmaceutical, Chugai Pharmaceutical, Bayer, Pfizer, Bristol-Myers Squibb, Miyarisan Pharmaceutical, and Yakult Pharmaceutical Industry. S.K. received a consulting or advisory role, speakers bureau, and research funding from Bayer and Eisai. N.I. received speakers bureau from Eisai and Bayer. N.K. received honoraria, a consulting or advisory role, and research funding from Bayer and Eisai. M. Kudo received honoraria from Bayer, Eisai, Merck & Co. Inc., and Ajinomoto, consulting or advisory frees from Kowa, Merck & Co. Inc., Bristol-Myers Squibb, Chugai Pharmaceutical, and Taiho Pharmaceutical, and research grants from Chugai Pharmaceutical, Otuka, Takeda, Sumitomo Dainippon Pharma, Daiichi Sankyo, Merck & Co., Eisai, Bayer, and Abbvie. M.O. received honoraria from Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Otsuka, Astellas, Gilead Science, Chugai Pharmaceutical, Mitsubishi Tanabe, Kyorin, Merck Sharp and Dohme, Sumitomo Dainippon, Vertex Pharmaceutical, Takeda, Merck Serono, and Zeria. The other authors involved in this study have nothing to declare regarding funding or conflicts of interest.